Lantheus (NASDAQ:LNTH) Price Target Increased to $127.00 by Analysts at SVB Leerink

Lantheus (NASDAQ:LNTH) had its price target hoisted by SVB Leerink from $106.00 to $127.00 in a report published on Thursday morning, Benzinga reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently issued reports on the company. Truist Financial boosted their price target on Lantheus from $82.00 to $96.00 and gave the company a buy rating in a research report on Friday, May 3rd. B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a buy rating in a research report on Thursday, April 18th. Mizuho boosted their price target on Lantheus from $90.00 to $100.00 and gave the company a buy rating in a research report on Friday, May 3rd. JMP Securities boosted their price target on Lantheus from $100.00 to $130.00 and gave the company an outperform rating in a research report on Wednesday. Finally, StockNews.com cut Lantheus from a buy rating to a hold rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of Moderate Buy and a consensus price target of $113.86.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $123.62 on Thursday. The company has a market cap of $8.57 billion, a P/E ratio of 18.87 and a beta of 0.51. The company has a quick ratio of 4.55, a current ratio of 4.84 and a debt-to-equity ratio of 0.59. Lantheus has a 52 week low of $50.20 and a 52 week high of $124.90. The business has a fifty day simple moving average of $81.01 and a 200-day simple moving average of $67.35.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.11. The business had revenue of $369.98 million during the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. Equities research analysts forecast that Lantheus will post 6.46 EPS for the current year.

Insider Buying and Selling

In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Lantheus news, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now owns 23,340 shares in the company, valued at $1,848,294.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now directly owns 62,557 shares of the company’s stock, valued at $4,990,171.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,269 shares of company stock worth $2,557,300. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently made changes to their positions in LNTH. Vanguard Group Inc. grew its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after buying an additional 389,828 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after buying an additional 394,837 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares in the last quarter. Reinhart Partners LLC. grew its holdings in Lantheus by 8.4% in the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider’s stock worth $91,517,000 after buying an additional 114,110 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in Lantheus by 41.9% in the 3rd quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock worth $90,387,000 after buying an additional 384,093 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.